1. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474. Br J Pharmacol39:675-675, 1970
2.
2. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol39:657-657, 1970
3.
3. Singh BN. Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol81 (6A):3D-3D, 1998
4.
4. Singh BN. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol10:283-283, 1999
5.
5. Feld GK. Evolution of diagnostic and interventional cardiac electrophysiology: Historical review. Am J Cardiol84 (9R):115R-115R, 1999
6.
6. Marchlinski FE, Zado ES, Deely MP, et al. Concomitant device and drug therapy: Current trends, potential benefits, and adverse interactions. Am J Cardiol84 (9A):69R-69R, 1999
7.
7. Singh BN. Routine prophylactic lidocaine administration in acute myocardial infarction. An idea whose time is all but gone?Circulation86:1033-1033, 1992
8.
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary Report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med321:406-406, 1989
9.
9. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med327:227-227, 1992
10.
10. Hallstrom AP, Cobb LA, Yu BH, et al. An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol68:1025-1025, 1991
11.
11. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. A metaanalysis of randomized control trials. Circulation82:1106-1106, 1990
12.
12. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol20:427-427, 1992
13.
13. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation84:1977-1977, 1991
14.
14. Mason JW, ESVEM Investigators. A randomized comparison of electrophysiologic study to electrocardiographic monitoring for prediction of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. N Engl J Med329:445-445, 1993
15.
15. Mason JW, ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med329:452-452, 1993
16.
16. The CASCADE Investigators. The Cascade StudyRandomized Anti-Arrhythmic Drug Therapy in Survivors of Cardiac Arrest in Seattle. Am J Cardiol72:280-280, 1993
17.
17. Wang Z, Pelletier LC, Talajic M, et al. Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation82:274-283, 1990
18.
18. Zipes DP. An overview of arrhythmias and antiarrhythmic approaches. J Cardiovasc Electrophysiol10:267-267, 1999
19.
19. Camm AJ, Yee Guan Yap. What should we expect from the next generation of antiarrhythinic drugs?J Cardiovasc Electrophysiol10:307-307, 1999
20.
20. The AFFIRM Investigators. Atrial fibrillation following investigation of rhythm management: AFFIRM Study Design. Am J Cardiol79:1198-1198, 1997
21.
21. SAFE-T Investigators. The effects of antiarrhythmic therapy in maintaining stability of sinus rhythm in atrial fibrillation. VA Cooperative Study #399 (1998-2002)
22.
22. The Antiarrhythmics versus implantable defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med337:1576-1583, 1997
23.
23. Connolly SJ, Gent M, Roberts RS, et al. for the CIDS Investigators. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation101:1297-1297, 2000
24.
24. Kuck K-H, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation102:748-754, 2000
25.
25. Moss AJ, Hall WJ, Cannom DS, et al. for the Multicenter Automatic Defibrillator Implantation Investigators. Improved survival with an implantable defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmias. N Engl J Med335:1933-1933, 1996
26.
26. Buxton AE, Lee KL, Fisher JD, et al. for the Multicenter Unsustained Tachycardia Trial. N Engl J Med341:1882-1882, 1999
27.
27. Domansky M, Sakseena S, Epstein AE, et al. Relative effectivenes of the implantable cardioverterdefibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular function who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics versus implantable defibrillators. J Am Coll Cardiol34 (4):1090-1090, 1999
28.
28. Metoprolol in Dilated Cardiomyopathy Trial Study Group. Three-year follow patient randomized in the metoprolol in dilated cardiomyopathy trial. Lancet351:1180-1180, 1998
29.
29. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart failure (Merit-HF). Lancet353:2001-2001, 1999
30.
30. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation90:1765-1765, 1994
31.
31. The CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial. Lancet353:9-9, 1999
32.
32. Packer M, Colucci WS, Sackner-Bermstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The Precise Trial. Circulation94:2793-2793, 1996
33.
33. Australia/New Zealand Heart Failure Research Group. Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet349:375-375, 1997
34.
34. Amiodarone Trials Meta-Analysis Investigators. Efficacy of prophylaxis of amiodarone on mortality after myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6,500 patients in randomized trials. Lancet350:1417-1417, 1997
35.
35. Boutitie F, Boissel JP, Connolly SJ, et al. and the EMIAT and CAMIAT Investigators. Amiodarone interaction with beta-blockers: Analysis of merged EMIAT and CAMIAT data bases. Circulation99:2268-2268, 1999
36.
36. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev69:1049-1049, 1989
37.
37. Yusuf S, Teo KK. Approaches to prevention of sudden death: Need for fundamental reevaluation. J Cardiovasc Electrophysiol2 (3):S233-S233, 1991
38.
38. Schwartz PJ. The idiopathic long QT interval syndrome: Progress and questions. Am Heart J109:399-399, 1985
39.
39. Steinbeck G, Andersen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with betablocker therapy to patients with symptomatic sustained tachyarrhythmias. N Engl J Med327:987-987, 1992
40.
40. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during myocardial infarction: An overview of randomized trials. Prog Cardiovasc Dis27:335-335, 1985
41.
41. Singh BN. The coming of age of the class III antiarrhythmic principle: Retrospective and future trends. Am J Cardiol78(suppl 4A):17-27, 1996
42.
42. Reiter MJ, Reiffel JA. Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol82 (4A):91-91, 1998
43.
43. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation100:2025-2025, 1999
44.
44. Singh BN (Ed). A symposium: Controlling cardiac arrhythmias by sotalol, a broad-spectrum antiarrhythmic with beta-blocking effects and class III activity. Am J Cardiol65(2):1-88, 1990
45.
45. Polster P, Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol25:131-131, 1976
46.
46. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol39:668-674, 1970
47.
47. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action. Mechanism of potassium-channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation82:2235-2235, 1990
48.
48. Sanguinetti MS, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current: Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol96:194-194, 1990
49.
49. Stambler BS, Wood MA, Ellenbogen K, et al. Efficacy of safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation94:1613-1613, 1996
50.
50. Singh BN. Acute conversion of atrial flutter and fibrillation: Direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol29:391-391, 1997
51.
51. Roden DM. Ibutilide and the treatment of atrial arrhythmias. A new drug-almost unheralded-is now available to US physicians. Circulation94:1499-1499, 1996
52.
52. Doshi S, Singh BN. Class III antiarrhythmic drugs in atrial fibrillation: Focus on dofetilide. J Cardiovasc Pharmacol Ther5(4):237-237, 2000
53.
53. Singh BN, Hauswirth O. Comparative mechanisms of action of antlarrhythmic drugs. Am Heart J87:367-367, 1974
54.
54. Benditt DG, Williams JH, Jin J, et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol84:270-270, 1999
55.
55. Singh BN. Sotalol: Current status and expanding indications. J Cardiovasc Pharmacol Therapeut4(1):49-49, 1999
56.
56. Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol76:47-47, 1995
57.
57. Daoud EG, Strickenberger AS, Man C, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med37:1785-1785, 1997
58.
58. Singh BN, Mody FV, Lopez B, et al. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Am J Cardiol84:161R-161R, 1999
59.
59. Roy D, Talajic M, Dorian P, et al. for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med342:913-913, 2000
60.
60. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol81:995-995, 1998
61.
61. Singh BN. Amiodarone: The expanding role and how to follow a patient on chronic therapy. Clin Cardiol20:608-608, 1997
62.
62. Hohnloser S, Klingenheben T, Singh BN. Amiodaroneassociated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Intern Med121:529-529, 1994
63.
63. Singh BN, Wellens HJJ, Hiraoka M. Electropharmacological Control of Cardiac Arrhythmias. To Delay Conduction or to Prolong Refractoriness?Futura Publishing, Mt Kisco, NY, pp. 1-743, 1993
64.
64. Papp J Gy, Nemeth M, Krassoi I, et al. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Therap1(4):187-187, 1996
65.
65. Sicouri M, Moro S, Litovsky S, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol8:1269-1269, 1997
66.
66. Hondeghem LM, Snyder DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and danger of reverse use dependence. Circulation81:686-686, 1990
67.
67. Singh BN. Antiarrhythmic actions of amiodarone: A profile of a paradoxical agent. Am J Cardiol78:41-41, 1996
68.
68. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol84(9A):11R-11R, 1999
69.
69. Takanaka C, Singh BN. Barium-induced non-driven action potentials as a model of triggered potentials from early afterdepolarization: Significance of slow-channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol15(1):213-213, 1990
70.
70. Cui G, Sen L, Sager PT, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol75:465-465, 1995
71.
71. Singh BN. Expanding indications for the use of class III antiarrhythmic agents in patients at high risk for sudden death. J Cardiovasc Electrophysiol6:887-887, 1995
72.
72. Singh BN (ed): A symposium: Approaches to controlling cardiac arrhythmias: Focus on amiodarone, the last 15 years. Am J Cardiol84(9A):1R-173R, 1999
73.
73. Pacifico A, Hohnloser SH, Williams JH, et al. for the d,lSotalol Implantable Defibrillator Study Group. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med340:1855-1855, 1999
74.
74. Kowey PR, Levine JH, Pacifico A, et al. for the Intravenous Amiodarone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with hemodynamically destabilizing ventricular tachycardia and fibrillation. Circulation92:3255-3255, 1995
75.
75. Scheinman MM, Levine JH, Cannom DS, et al. for the Intravenous Amiodarone Multicenter Investigators' Group: Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation92:3264-3264, 1995
76.
76. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med341:871-871, 1999
77.
77. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res35:13-13, 1997
78.
78. Singh BN. Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact. Eur Heart J14:29-29, 1993
79.
79. Singh BN, Venkatesh N, Nademanee K, et al. The historical development, cellular electrophysiology, and pharmacology of amiodarone. Prog Cardiovasc Dis31:249-249, 1989
80.
80. Sager PT, Uppal P, Follmer CT, et al. The frequencydependent electrophysiologic effects of amiodarone in humans. Circulation88:1063-1063, 1993
81.
81. Hohnloser S, Klingenheben T, Singh BN. Amiodaroneassociated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Intern Med121:529-529, 1994
82.
82. Kodama I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol84(9A):20R-20R, 1999
83.
83. Antimisiaris M, Sarma JSM, Schoenbaum MP, et al. Effects of amiodarone on the circadian rhythm and power spectral analysis of heart rate and QT interval: Significance of the control sudden cardiac death. Am Heart J128:884-884, 1994
84.
84. Roden DM. Mechanisms underlying variability in response to drug therapy: Implications for amiodarone use. Am J Cardiol84:29R-29R, 1999
85.
85. Singh SN, Fletcher RD, Fisher S, et al. Amiodraone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med333:77-77, 1995
86.
86. Hamer AWF, Arkles B, Johns JA. Beneficial effects of low-dose amiodarone in patients with congestive heart failure: A placebo-controlled trial. J Am Coll Cardiol14:1768-1768, 1989
87.
87. Nasir N, Swama US, Boahene KA, et al. Therapy of susained ventricular arrhythmias with amiodarone: Prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Therap1:123-123, 1996
88.
88. Pollak TP. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary. Am J Cardiol84(9A):37R-37R, 1999
89.
89. Latham KR, Seletti DF, Goldstein RE. The effects of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J Am Coll Cardiol7:472-450, 1987
90.
90. Norman MF, Lavin TA. Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells. J Clin Invest83:306-313, 1989
91.
91. van Beeren HC, Bakker O, Weirsinga WM. Structurefunction relationship of inhibition of the 3,5,3'-triidothyronine binding to the alpha 1 and beta 1-thyroid hormone receptor by amiodarone analogs. Endocrinology137:2807-2807, 1996
92.
92. Manning A, Bruyninckx C, Hodeige D, et al. SR 33589, a new amiodarone-like antiarrhythmic agent. Br J Pharmacol107 (suppl 1):270P-270P, 1992
93.
93. Hodeige D, Heyndrickx JP, Chatelain P, et al. SR33589, a new amiodarone-like antiarrhythmic agent: Anti-adrenoceptor activity in anesthetized and conscious dogs. Eur J Pharmacol279:25-25, 1995
94.
94. Manning A, Thisse V, Hodeige D, et al. SR33589, a new amiodarone-like antiarrhythmic agent: Electrophysiologic effects in anesthetized dogs. J Cardiovasc Pharmacol25(2):252-252, 1995
95.
95. Finance O, Pianchenault J, Bethignes S, et al. Electrophysiological and hemodynamic effects of a new amiodarone-like agent following acute and chronic administration in anaesthetized dogs. J Mol Cell Cardiol30(7):A251-A251, 1998
96.
96. Finance O, Manning A, Chatelain P. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, d,l-sotalol, and lignocaine on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol26:570-570, 1995
97.
97. Manning AS, Bruyninckx C, Ramboux J, et al. SR33589, a new amiodarone-like agent: Effect on ischemiaand reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol26:453-461, 1995
98.
98. Finance O, Planchenault J, Bethgnies S, et al. Electrophysiological and antifibrillatory actions of a new amiodarone-like agent dronedarone, in experimental atrial fibrillation. J Mol Cell Cardiol30(7):A251-A251, 1998
99.
99. Sun W, Sarma JSM, Singh BN. Electrophysiologic effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone. Circulation100:2276-2276, 1999
100.
100. Guillemare E, Marion A, Nisato D, et al. Acute effects of dronedarone and amiodarone on 1KI, lKr, IKS in guinea pig ventricular myocytes. Fund Clin Pharmacol13:389-389, 1999
101.
101. Guilemare E, Gautier P, Nisato D. Effects of dronedarone on calcium handling in cardiac ventricular myocytes. Eur Heart J20:329-329, 1999
102.
102. Sun W, Sarma JSM, Steele SS, et al. Electrophysiologic effects of long-term treatment with SR 33589 on rabbit atrial muscle. Comparison with amiodarone. J Am Coll Cardiol33 (suppl A): 131A-131A, 1999
103.
103. Sun W, Sarma JSM, Singh BN. Acute and chronic effects of dronedarone on the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. Submitted for publication, 2001
104.
104. Watanabe Y, Hara Y, Tamagawa M, Nakaya H. Inhibitory effects of amiodarone on the muscarinic acetylcholine Mechanisms of Antiarrhythmic Drugs and Origin of Arrhythmias * Singh and Sarma 87 receptor-operated potassium current in guinea pig atrial cells. J Pharmacol Exp Ther279:617-624, 1996
105.
105. Gautier P, Marion A, Bertrand JP, et al. Electrophysiological characterization of dronedarone (SR 33589), a new amiodarone-like agent, in cardiac ventricular myocytes. Eur Heart J18(suppl):269-269, 1997
106.
106. Aimond F, Beck L, Gautier P, et al. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J Pharm Exp Ther292:415-415, 2000
107.
107. Vaughan Williams EM, Polster P. The effect on cardiac muscle of two drugs, related to amiodarone, L8040 and L8462. Eur J Pharmacol25:241-241, 1974
108.
108. Sarma JSM, Singh BN, Radzik D, et al. Dose-dependent effects of dronedarone on the circadian patterns of RR and QT intervals in healthy subjects. Presented at the American Heart Association 73rd Scientific Sessions, Nov. 2000
109.
109. Camm AJ, Yap GY. What should we expect from the next generation of antiarrhythmic drugs?J Cardiovasc Electrophysiol10:307-307, 1999
110.
110. Tomaselli GF, Rose J. Molecular aspects of arrhythmias associated with cardiomyopathies. Curr Opin Cardiol15:202-202, 2000
111.
111. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. International Consensus on Science. Circulation102:8(suppl)1-1-383-1-1-383, 2000
